Grifols (GRF) Q3 2025 earnings summary

Executive summary

• Year-to-date Q3 2025 revenue reached €5.542 billion, up 7.7% at constant currency, with strong growth in immunoglobulins and Alpha-1 franchises driven by disciplined execution and innovation.

• Adjusted EBITDA for YTD Q3 2025 was €1,358 million, up 11.2% at constant currency, with margin expansion to 24.5%.

• Free cash flow pre-M&A and pre-dividends improved by €257 million year-over-year, reaching €188 million YTD.

• Leverage ratio improved to 4.2x from 5.1x in the prior year, reflecting ongoing deleveraging.

• Value Creation Plan and commercial execution remain central, with robust pipeline and innovation initiatives.

Financial highlights

• Q3 2025 net revenue was €1,865 million, up 9.1% at constant currency year-over-year.

• Q3 adjusted EBITDA was €482 million (25.8% margin); YTD adjusted EBITDA margin was 24.5%, up 60bps year-over-year.

• YTD group profit was €304 million, up over 245% versus 2024.

• Free cash flow pre-M&A and pre-dividends for Q3 was €203 million.

• Gross margin for Q3 was 39.3%, up 50bps year-over-year.

Outlook and guidance

• FY 2025 revenue guidance raised to above €7,600 million at guidance FX rates.

• Adjusted EBITDA guidance reaffirmed at €1,875–1,925 million.

• Free cash flow pre-M&A and pre-dividends guidance improved to €400–425 million.

• Full-year FX headwind on adjusted EBITDA estimated at €70 million; impact on group profit, FCF, and leverage expected to be neutral.

• Expect robust Q4, but comparison to Q4 2024 will be less favorable due to prior phasing benefits.